Additionally, the fact that NCI-H460 cells have wild-type p53 (Mitsudomi et al, 1992), while the Calu-6 cells harbour mutated p53 (Lehman et al, 1991), demonstrate that the in vivo growth inhibition of the two human NSCLC cell lines by GS-168AT2 is independent of the p53 genotype and it is most probably due to the antiangiogenic activity of GS-168AT2. This evidence concerns the gene TP53 and non-small cell lung carcinoma.